filmov
tv
GPRC5D and FCRH5 Targeted Therapies in Myeloma
Показать описание
Recorded on June 15th, 2023 as part of the Relapsed/Refractory Myeloma Chapter in the Myeloma Community Program by HealthTree with Dr. Benjamin Diamond.
Follow HealthTree:
Follow HealthTree:
1:02:21
GPRC5D and FCRH5 Targeted Therapies in Myeloma
0:02:14
Going beyond BCMA-targeting agents in myeloma: GPRC5D and FcRH5-targeting therapies
0:05:21
Beyond BCMA: GPRC5D & FcRH5
0:00:41
FcRH5 & GPRC5D bispecific antibodies: antigen targets beyond BCMA for multiple myeloma
0:01:33
Emerging therapies for multiple myeloma and excitement in the GPRC5D space
0:01:24
Bispecifics & CARs: BCMA, GPRC5D & FcRH5 sequencing
0:01:47
A New Target for CAR-T Therapy in Myeloma - GPRC5D | Fredrik Schjesvold, MD | ASH 2021
0:01:10
The importance of BCMA, FcRH5 and GPRC5D in multiple myeloma
0:06:58
GPRC5D-Targeted CAR T-Cell Therapy for RRMM: Phase 1 Study Outcomes of BMS-986393 (CC-95266)
0:00:48
Myeloma: the groovy new GPRC5D
0:20:18
Overview of BCMA & Other Targets in Myeloma - Alexander Lesokhin, MD | MCRT Webcast Apr 10, 2021
0:01:10
BMS-986393: GPRC5D-targeted CAR for R/R myeloma
0:01:48
Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
0:23:28
The Future of Myeloma: Immune Therapy & Targets - Andrew Cowan, MD | MCRT Webcast November 21 (8...
0:06:35
The benefits of bispecific antibodies for treating multiple myeloma
0:01:21
Novel targets and the future role of combinations for myeloma
0:02:06
Safety & efficacy of cevostamab in patients with heavily pre-treated R/R multiple myeloma
0:02:53
Novel targets and dual-targeting approaches in myeloma
0:04:15
Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
0:02:48
Novel targets in multiple myeloma
0:19:00
Symposium | Beyond BCMA: Novel strategies using bispecific antibodies
0:06:45
Phase I trial of a FcRH5-targeted BiTE in R/R myeloma
0:01:16
Latest advances in immunotherapy for multiple myeloma: targets, alloCAR-Ts & immunomodulatory dr...
0:08:06
Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMM
Комментарии